Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

101566

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to increase his Department's budget for research and development.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	212377
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Planned expenditure from the research and development budget in 2014-15 is £1,077 million, which in cash terms, represents an increase of 26% in comparison with spend in 2009-10.</p><p> </p><p> </p><p> </p><p>A budget figure for 2015-16 has not yet been set. This will happen as part of standard business planning later this year.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:35:58 answering member 4020 label Biography information for George Freeman
tabling member	3931 label Biography information for Dr Julian Huppert

101579

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he plans to take to ensure that the payments made by the pharmaceutical industry under the Pharmaceutical Price Regulation Scheme will be apportioned to each of the devolved health administrations, whilst securing that the mechanism in place for determining apportionment ensures that patients in all four constituent parts of the UK receive benefits from the payments made throughout the duration of the scheme.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212420
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way. Under the new arrangements introduced as part of the 2014 scheme, the apportionments will be agreed with the devolved administrations each year. The method for apportioning 2014-15 payments has not yet been finalised.</p><p> </p><p> </p><p> </p><p>It is a matter for the devolved health administrations to decide how to use the apportioned payments they receive from the PPRS.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:36:17 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101416

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the effect of the National Institute for Health and Care Excellence's health technology appraisals on pancreatic cancer research.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	212353
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>We have made no such assessment.</p><p> </p><p> </p><p> </p><p>The National Institute for Health Research is investing £6.5 million over five years to 2017 in the Liverpool Pancreas Biomedical Research Unit. This unit is working in partnership with industry and leading research institutions to develop new treatments and diagnostic strategies for pancreatic cancer, so advancements in science can lead to benefits for patients.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:38:12 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

101417

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 22 October 2014 to Question 210807, what the anticipated payments in England were in 2014-15; whether those anticipated payments have been passed to NHS England through the mandate in full; and whether the actual rebate payments for 2014-15 are on course to match or exceed those anticipated payments.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	212344
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The anticipated Pharmaceutical Price Regulation Scheme (PPRS) payment for 2014-15 in respect of England was estimated to be £375 million and this was taken into account when setting the 2014-15 NHS England Mandate and overall NHS budget.</p><p> </p><p> </p><p> </p><p>The actual amount received in financial year 2014-15 will depend on actual sales covered by the PPRS in Quarters 2-4 2014 and Quarter 1 in 2015, and also on the adjusted payment percentage for 2015 which will affect Quarter 1 2015.</p><p> </p><p> </p><p> </p><p>The Government has committed to publishing PPRS payment data quarterly. In line with this commitment, the Department has published the first two quarters PPRS payments for 2014 and will be announcing the third and fourth quarter payments, which will depend on growth in those quarters, together with the adjusted payment percentage for 2015, in due course.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212300 question first answered 03/11/2014 17:39:18 answering member 4020 label Biography information for George Freeman
tabling member	3931 label Biography information for Dr Julian Huppert

101420

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Terminal Illnesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether health technology appraisal committees can apply the National Institute for Health and Care Excellence's end-of-life criteria flexibly when appraising treatments for patients with terminal illness.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	212351
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Appraisal Committees are independent advisory bodies responsible for making recommendations to the National Institute for Health and Care Excellence (NICE) on the clinical and cost effectiveness of treatments for use in the National Health Service.</p><p> </p><p> </p><p> </p><p>NICE’s <em>Guide to the Methods of Technology Appraisal</em> is published at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/PMG9/chapter/Foreword" target="_blank">www.nice.org.uk/article/PMG9/chapter/Foreword</a></p><p> </p><p> </p><p> </p><p>and describes how its Appraisal Committees reach decisions on treatments. It provides details of the criteria that need to be met in order to apply greater flexibility in the appraisal of life-extending drugs for patients at the end of their lives.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:33:34 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

101422

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 22 October 2014 to Question 210807, what the anticipated payments were in respect of England in 2014-15; whether the anticipated payments have been passed to NHS England through the mandate; and whether the actual rebate payments for 2014-15 are on course to match or exceed those anticipated payments.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	212300
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The anticipated Pharmaceutical Price Regulation Scheme (PPRS) payment for 2014-15 in respect of England was estimated to be £375 million and this was taken into account when setting the 2014-15 NHS England Mandate and overall NHS budget.</p><p> </p><p> </p><p> </p><p>The actual amount received in financial year 2014-15 will depend on actual sales covered by the PPRS in Quarters 2-4 2014 and Quarter 1 in 2015, and also on the adjusted payment percentage for 2015 which will affect Quarter 1 2015.</p><p> </p><p> </p><p> </p><p>The Government has committed to publishing PPRS payment data quarterly. In line with this commitment, the Department has published the first two quarters PPRS payments for 2014 and will be announcing the third and fourth quarter payments, which will depend on growth in those quarters, together with the adjusted payment percentage for 2015, in due course.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212344 question first answered 03/11/2014 17:39:18 answering member 4020 label Biography information for George Freeman
tabling member	3931 label Biography information for Dr Julian Huppert

101423

registered interest
date	28/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Terminal Illnesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons the National Institute for Health and Care Excellence advises that end-of-life criteria should only apply to medicines that extend life by at least three months.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	212356
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>I refer the hon. Member to my answer of 28 October 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-questions-answers/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=211807" target="_blank">211807</a>.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:31:01 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

101149

registered interest
date	27/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent representations he has received on extending the right to free prescriptions to all asthma patients; and if he will make a statement.
tabling member constituency	Warrington North
tabling member printed	Helen Jones
uin	212053
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>We are unable to make such an estimate.</p><p> </p><p> </p><p> </p><p>Data on the cost to the National Health Service of treating asthma patients in accident and emergency or unplanned hospital admissions is not collected by the Department. The Health and Social Care Information Centre (HSCI) has published information on reasons, for example respiratory problems, for accident and emergency attendance in its <em>Hospital Episode Statistics: Accident and Emergency Attendances in England 2012-13</em>, but this does not identify specific conditions, such as asthma, that may have prompted an accident and emergency visit or unplanned hospital admission.</p><p> </p><p> </p><p> </p><p>Since 1 November 2013, the Department has received 44 representations through the Department’s Ministerial correspondence unit and two parliamentary questions, including the hon. Member’s own, regarding extending exemption from prescription charging to people with asthma.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212052 question first answered 30/10/2014 16:45:13 answering member 4020 label Biography information for George Freeman
tabling member	432 label Biography information for Helen Jones

101150

registered interest
date	27/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will estimate the potential saving from extending free prescriptions to all asthma patients arising from reductions in accident and emergency visits and unplanned hospital admissions; and if he will make a statement.
tabling member constituency	Warrington North
tabling member printed	Helen Jones
uin	212052
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>We are unable to make such an estimate.</p><p> </p><p> </p><p> </p><p>Data on the cost to the National Health Service of treating asthma patients in accident and emergency or unplanned hospital admissions is not collected by the Department. The Health and Social Care Information Centre (HSCI) has published information on reasons, for example respiratory problems, for accident and emergency attendance in its <em>Hospital Episode Statistics: Accident and Emergency Attendances in England 2012-13</em>, but this does not identify specific conditions, such as asthma, that may have prompted an accident and emergency visit or unplanned hospital admission.</p><p> </p><p> </p><p> </p><p>Since 1 November 2013, the Department has received 44 representations through the Department’s Ministerial correspondence unit and two parliamentary questions, including the hon. Member’s own, regarding extending exemption from prescription charging to people with asthma.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212053 question first answered 30/10/2014 16:45:13 answering member 4020 label Biography information for George Freeman
tabling member	432 label Biography information for Helen Jones

100716

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the Risk Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211709
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211707 211708 211710 question first answered 30/10/2014 16:13:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne